Sunshine Biopharma Inc.

Nasdaq:SBFMNasdaq:SBFMW

Pharmaceutical Preparations·FORT LAUDERDALE, FL

CEO

Slilaty Steve N.

CFO

Sebaaly Camille

Financials

20 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/13/25	→
10-Q	Q2 2025	6/30/25	8/12/25	→
10-Q	Q1 2025	3/31/25	5/15/25	→
10-K	FY 2024	12/31/24	4/1/25	→
10-Q	Q3 2024	9/30/24	11/5/24	→
10-Q/A	Q2 2024	6/30/24	8/20/24	→
↓

Earnings Releases (8-K)

9 shown

Filed	Period
5/19/25	Q2 FY2025	→
4/2/25	Q1 FY2025	→
11/7/24	Q4 FY2024	→
8/19/24	Q3 FY2024	→
5/22/24	Q2 FY2024	→
4/1/24	Q1 FY2024	→
↓

News (8-K)

71 shown

Filed	Type	Description
2/20/26	Vote	Submission of Matters to a Vote of Security Holders	→
2/5/26	Exec Change	Departure or Appointment of Directors or Certain Officers	→
12/12/25	Vote	Submission of Matters to a Vote of Security Holders	→
9/30/25	Other	Changes in Registrant's Certifying Accountant	→
4/3/25	Agreement	Entry into a Material Definitive Agreement	→
1/15/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
↓

Prospectuses & Registrations

30 shown

Filed	Form	Description
8/12/25	424B3	424B3	→
8/5/25	S-1	S-1	→
4/3/25	424B5	424B5	→
1/6/25	S-3	REGISTRATION STATEMENT	→
11/12/24	424B4	424B4	→
2/14/24	424B4	424B4	→
↓

Filing History(378 filings)

TypeDateAccessionPeriodSize

DEF 14C

Mar 2, 2026

0001683168-26-001410FORM DEF 14C

Mar 2, 2026

74.1 KB

8-K

Feb 20, 2026

0001683168-26-001216CURRENT REPORT

Feb 18, 2026

231.4 KB

PRE 14C

Feb 20, 2026

0001683168-26-001215PRELIMINARY INFORMATION STATEMENT

Feb 18, 2026

74.1 KB

8-K

Feb 5, 2026

0001683168-26-000789CURRENT REPORT

Feb 5, 2026

226.7 KB

8-K

Dec 12, 2025

0001683168-25-009103FORM 8-K

Dec 11, 2025

235.5 KB

10-Q

Nov 13, 2025

0001683168-25-008328FORM 10-Q FOR SEP 2025

Sep 30, 2025

3.5 MB

DEFA14A

Oct 23, 2025

0001683168-25-007749FORM DEFA 14A

—

265.1 KB

DEF 14A

Oct 23, 2025

0001683168-25-007747DEFINITIVE PROXY

Dec 11, 2025

257.0 KB

8-K

Sep 30, 2025

0001683168-25-007338CURRENT REPORT

Sep 24, 2025

233.1 KB

SCHEDULE 13G/A

Aug 14, 2025

0002000324-25-002749

—

11.3 KB

EFFECT

Aug 12, 2025

9999999995-25-002587

—

2.0 KB

10-Q

Aug 12, 2025

0001683168-25-005981FORM 10-Q FOR JUN 2025

Jun 30, 2025

3.8 MB

424B3

Aug 12, 2025

0001683168-25-005978PROSPECTUS

—

58.8 KB

Aug 12, 2025

0001683168-25-005976FORM RW

—

6.4 KB

UPLOAD

Aug 11, 2025

0000000000-25-008396

—

39.6 KB

CORRESP

Aug 11, 2025

0001683168-25-005883

—

6.0 KB

S-1

Aug 5, 2025

0001683168-25-005644FORM S-1

—

512.3 KB

POS AM

Jul 25, 2025

0001683168-25-005404POST-EFFECTIVE AMENDMENT #2

—

380.9 KB

SCHEDULE 13G/A

Jun 12, 2025

0000921895-25-001755

—

10.0 KB

SCHEDULE 13G

May 23, 2025

0001213900-25-047357

—

15.2 KB

8-K

May 19, 2025

0001683168-25-003838CURRENT REPORT

May 15, 2025

255.8 KB

10-Q

May 15, 2025

0001683168-25-003701FORM 10-Q FOR MAR 2025

Mar 31, 2025

3.5 MB

SCHEDULE 13G

Apr 11, 2025

0000921895-25-001064

—

16.6 KB

8-K

Apr 3, 2025

0001683168-25-002245CURRENT REPORT

Apr 2, 2025

865.8 KB

424B5

Apr 3, 2025

0001683168-25-002241424B5

—

220.6 KB

25 filings shown

Sunshine Biopharma Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(378 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/2/26	DEF 14C	FORM DEF 14C	→
2/20/26	PRE 14C	PRELIMINARY INFORMATION STATEMENT	→
10/23/25	DEFA14A	FORM DEFA 14A	→
10/23/25	DEF 14A	DEFINITIVE PROXY	→
10/17/24	DEF 14A	DEFINITIVE PROXY STATEMENT	→
7/11/24	DEF 14C	DEFINITIVE PROXY	→
↓

Filed	Form	Description
1/21/25	3	3	→
11/14/24	SC 13G/A	SC 13G/A	→
3/5/24	4	4	→
2/23/24	SC 13G	SCHEDULE 13G	→
2/21/24	SC 13G	SCHEDULE FILED TO REPORT ACQUISTION OF BENEFICAL OWNERSHIP	→
2/14/24	SC 13G	SC 13G	→
↓

Filed	Form	Description
8/14/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
8/12/25	EFFECT	EFFECT	→
8/12/25	RW	FORM RW	→
7/25/25	POS AM	POST-EFFECTIVE AMENDMENT #2	→
6/12/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
5/23/25	SCHEDULE 13G	SCHEDULE 13G	→
↓